Reversal Agent Won’t Work with Dabigatran
A new reversal agent that is designed to help prevent patients from bleeding to death after taking some anticoagulant medications like Warfarin has been approved by the FDA. However, the...
Dabigatran Still Popular for AF Despite Bleeding Risks
Even while the anticoagulant AF drug Dabigatran (Pradaxa) has been linked to serious and uncontrollable bleeding risks, the pills are still selling at an alarmingly brisk rate. In fact, the...
Practical Guide to AF Anticoagulants Released
The European Heart Rhythm Association (EHRA) and the European Society of Cardiology has issued a new “practical guide” for the use of anticoagulant medications for the treatment of AF. The...
AF Affects Men, Women Differently
With atrial fibrillation (AF) being the most common type of heart complication that affects the patient’s heart rhythms, various studies have looked into the best treatment options as well as...
ARCA to Work with Medtronic on Gencaro AF Clinical Trial
According to recent announcement by ARCA Biopharma, which creates therapies that are genetically targeted for treating heart diseases, it will join with Medtronic to perform a clinical trial (called GENETIC-AF)...